These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 32725719)
1. Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: A case report and literature review. Liang JY; Ye RX; Tian X; Zhang SQ; Zhang XB Dermatol Ther; 2020 Nov; 33(6):e14097. PubMed ID: 32725719 [TBL] [Abstract][Full Text] [Related]
2. Successful treatment of severe pityriasis rubra pilaris with secukinumab in a 3-year-old boy. Xu YH; Dong DD; Lin YF; Wang Q; Huang LM; Shi JQ Clin Exp Dermatol; 2022 Nov; 47(11):2043-2045. PubMed ID: 35906074 [TBL] [Abstract][Full Text] [Related]
3. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis. Boudreaux BW; Pincelli TP; Bhullar PK; Patel MH; Brumfiel CM; Li X; Heckman MG; Pittelkow MR; Mangold AR; Sluzevich JC Br J Dermatol; 2022 Nov; 187(5):650-658. PubMed ID: 35701384 [TBL] [Abstract][Full Text] [Related]
4. Methotrexate treatment in a case of juvenile pityriasis rubra pilaris. Boyd AH; Polcari IC Pediatr Dermatol; 2018 Jan; 35(1):e62-e63. PubMed ID: 29044698 [TBL] [Abstract][Full Text] [Related]
5. Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy. Müller H; Gattringer C; Zelger B; Höpfl R; Eisendle K J Am Acad Dermatol; 2008 Nov; 59(5 Suppl):S65-70. PubMed ID: 19119128 [TBL] [Abstract][Full Text] [Related]
6. Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris. Bonomo L; Levitt JO Cutis; 2018 May; 101(5):367-369. PubMed ID: 29894526 [TBL] [Abstract][Full Text] [Related]
7. Successful treatment of a child's pityriasis rubra pilaris (PRP) with ustekinumab and acitretin. Katharina M; Sylvia S; Matthias B; Ulrich M; Martin L Pediatr Dermatol; 2022 Jul; 39(4):659-661. PubMed ID: 35859269 [TBL] [Abstract][Full Text] [Related]
8. Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: A retrospective investigation. Maloney NJ; Hisaw LD; Worswick S Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 29034547 [TBL] [Abstract][Full Text] [Related]
9. Biologics for Treatment of Pityriasis Rubra Pilaris: A Literature Review. Chandy RJ; Chokshi A; Tan I; Feldman SR J Cutan Med Surg; 2024; 28(3):269-275. PubMed ID: 38549359 [TBL] [Abstract][Full Text] [Related]
10. Ustekinumab treatment of pityriasis rubra pilaris: A report of five cases. Napolitano M; Lembo L; Fania L; Abeni D; Didona D; Didona B J Dermatol; 2018 Feb; 45(2):202-206. PubMed ID: 29080273 [TBL] [Abstract][Full Text] [Related]
11. Adalimumab for the treatment of pityriasis rubra pilaris: a case report. Wassef C; Lombardi A; Rao BK Cutis; 2012 Nov; 90(5):244-7. PubMed ID: 23270195 [TBL] [Abstract][Full Text] [Related]
12. Systemic sclerosis in a patient with pityriasis rubra pilaris. Frikha F; Frigui M; Masmoudi H; Turki H; Bahloul Z Pan Afr Med J; 2010 Aug; 6():6. PubMed ID: 21436949 [TBL] [Abstract][Full Text] [Related]
13. Pityriasis rubra pilaris: treatment with biologics - a new promising therapy? Ivanova K; Itin P; Haeusermann P Dermatology; 2012; 224(2):120-5. PubMed ID: 22508269 [TBL] [Abstract][Full Text] [Related]
14. Role of IL-23 inhibitors including risankizumab and guselkumab in the treatment of pityriasis rubra pilaris. Rahman SM; Ahmed F; Haque A Arch Dermatol Res; 2024 Jun; 316(6):334. PubMed ID: 38844710 [TBL] [Abstract][Full Text] [Related]